Table 1. Clinicopathologic data of nine gastrointestinal stromal tumors.
| Patient | Sample | Tumor location | Size (cm) | Mitotic rate (per 5 mm2) | Risk of progression | KIT & PDGFRA mutation | Recurrence or metastasis | Clinical reponse to imatinib |
|---|---|---|---|---|---|---|---|---|
| 01 | 01 | stomach | 7 | 2 | low | wild-type | no | no treatment |
| 02 | 02 | stomach | 6 | 1 | Low | wild-type | no | no treatment |
| 03 | 03 | stomach | 6 | 6 | High | KIT exon 11 deletion | yes | Y |
| 04 | 04 | stomach | 12 | 9 | High | KIT exon 13 missense (K642E) | yes | Y |
| 05 | 05 | stomach | 6 | 3 | low | KIT exon 11 missense (V559A) | no | no treatment |
| 07 | 07 | small intestine (primary) | 12 | 10 | high | KIT exon 17 missense (N822Y) | yes | N |
| 08 | small intestine (recurrent) | 9 | 7 | |||||
| 08 | 09 | small intestine | 9 | 18 | high | KIT exon 11 deletion | yes | N |
| 09 | 10 | small intestine | 11 | 8 | high | KIT exon 9 insertion | yes | Y |
Y, stable disease or partial reponse; N, progressive disease